報價延遲最少15分鐘:2025/01/11 17:20 EST
|
|
|
|
|
||||||||||||
|
|
|
|
|
2.23 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-8.39/-1.11
|
|
企業價值
20.77M
|
| 資產負債 |
|
每股賬面淨值
0.90
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/01/11 17:20 EST
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. GeoVax's product pipeline includes ongoing humanclinical trials for a next-generation COVID-19 vaccine and a gene-directed therapy against head and neck cancers. Additional research and development programs include preventive vaccines against Monkeypox (MPox), hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg, and Lassa), and Zika virus, as well as immunotherapies for multiple solid tumors. |